Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Scholar Rock Holding (SRRK – Research Report). The associated price target remains the same with $50.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Andres Y. Maldonado has given his Buy rating due to a combination of factors surrounding Scholar Rock Holding’s promising developments. The company is at a crucial juncture with its lead product, apitegromab, which is making significant strides in the treatment of spinal muscular atrophy (SMA). The FDA’s acceptance of the Biologics License Application under Priority Review, along with the European Medicines Agency’s validation, positions Scholar Rock for a potential launch in the third quarter of 2025. This regulatory progress, combined with a strong commercial infrastructure and leadership team, supports the expectation of broad adoption of apitegromab.
Furthermore, the potential of apitegromab extends beyond SMA, as Scholar Rock is exploring its application in other neuromuscular diseases such as Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). The upcoming EMBRAZE trial results, which focus on muscle preservation in obese adults, could further enhance the drug’s profile. These factors, along with encouraging early payer interactions and the promising SAPPHIRE dataset, underscore the potential for significant market impact and justify the Buy rating.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as ImmunityBio, Day One Biopharmaceuticals, and Erasca. According to TipRanks, Y. Maldonado has an average return of -5.0% and a 30.61% success rate on recommended stocks.